Literature DB >> 11873030

Beneficial effects of short-term vasopressin infusion during severe septic shock.

Bhavesh M Patel1, Dean R Chittock, James A Russell, Keith R Walley.   

Abstract

BACKGROUND: Septic shock is associated with vasopressin deficiency and a hypersensitivity to its exogenous administration. The goal of the current study was to determine whether short-term vasopressin infusion in patients experiencing severe septic shock has a vasopressor sparing effect while maintaining hemodynamic stability and adequate end-organ perfusion.
METHODS: Patients experiencing septic shock that required high-dose vasopressor support were randomized to a double-blinded 4-h infusion of either norepinephrine (n = 11) or vasopressin (n = 13), and open-label vasopressors were titrated to maintain blood pressure. To assess end-organ perfusion, urine output and creatinine clearance, gastric mucosal carbon dioxide tension, and electrocardiogram ST segment position were measured.
RESULTS: Patients randomized to norepinephrine went from a median prestudy norepinephrine infusion of 20.0 microg/min to a blinded infusion of 17.0 mug/min at 4 h, whereas those randomized to vasopressin went from a median prestudy norepinephrine infusion of 25.0 microg/min to 5.3 microg/min at 4 h (P < 0.001). Mean arterial pressure and cardiac index were maintained in both groups. Urine output did not change in the norepinephrine group (median, 25 to 15 ml/h) but increased substantially in the vasopressin group (median, 32.5 to 65 ml/h; P < 0.05). Similarly, creatinine clearance did not change in the norepinephrine group but increased by 75% in the vasopressin group (P < 0.05). Gastric mucosal carbon dioxide tension and electrocardiogram ST segments did not change significantly in either group.
CONCLUSIONS: The authors conclude that short-term vasopressin infusion spared conventional vasopressor use and improved some measures of renal function in patients with severe septic shock.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873030     DOI: 10.1097/00000542-200203000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  106 in total

1.  Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock.

Authors:  Muhuo Ji; Renqi Li; Guo-min Li; Yunxia Fan; Lin Dong; Jianjun Yang; Yong G Peng; Jing Wu
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Impact of low-dose vasopressin on trauma outcome: prospective randomized study.

Authors:  Stephen M Cohn; Janet McCarthy; Ronald M Stewart; Rachelle B Jonas; Daniel L Dent; Joel E Michalek
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

3.  Vasopressin as adjunct vasopressor for vasodilatory shock due to non-occlusive mesenteric ischemia.

Authors:  G Luckner; S Jochberger; V D Mayr; H Knotzer; W Pajk; V Wenzel; B Friesenecker; I Lorenz; M W Dünser
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

4.  Noradrenaline and the kidney: foe, friend, or both?

Authors:  Martin Matejovic; Karl Träger; Daniel De Backer
Journal:  Intensive Care Med       Date:  2005-08-09       Impact factor: 17.440

5.  Current treatment of severe sepsis.

Authors:  Ismail Cinel; R Phillip Dellinger
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 6.  Sepsis: a clinical update.

Authors:  Corey E Ventetuolo; Mitchell M Levy
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-07       Impact factor: 8.237

7.  Acute kidney injury in sepsis: is renal blood flow more than just an innocent bystander?

Authors:  Martin Matejovic; Peter Radermacher; Michael Joannidis
Journal:  Intensive Care Med       Date:  2007-09       Impact factor: 17.440

Review 8.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

Review 9.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series.

Authors:  Stephanie M Boyd; Kristin L Riley; Regan E Giesinger; Patrick J McNamara
Journal:  J Perinatol       Date:  2020-09-19       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.